ABSTRACT
Study Objective
We sought to determine whether pilonidal disease (PD) is associated with polycystic
ovarian syndrome (PCOS) in adolescent females.
Design
Retrospective cohort study
Setting
Urban tertiary children's hospital
Participants
All girls aged 12 to 21 who received a diagnosis of PD and/or PCOS from 2012 to 2019
Interventions
Treatment for PCOS and PD
Main Outcome Measures
The variables analyzed included age, race/ethnicity, body mass index, age at menarche,
tobacco use, payer status, treatment of PCOS and PD, and serum markers of hyperandrogenism
and metabolic syndrome.
Results
During the study period, 100,043 patients presented to an urban tertiary medical center.
Of these patients, 966 were diagnosed with PD, and 219 were diagnosed with both PD
and PCOS. Compared with patients with only PD, patients with both diagnoses had a
higher body mass index (31.4 vs 27.4 kg/m2; P < .01) and were older (18.76 vs 18.30 years; P = .003). The prevalence ratio for patients with PD having PCOS per the original Rotterdam
criteria was 26.1 (CI, 22.0-31.0) and 28.7 (CI, 24.3-33.9) for having PCOS per the
modified Rotterdam criteria. Patients with both diagnoses were less likely to receive
intervention for PD (OR = 0.22; CI, 0.13-0.37; P < .001).
Conclusions
Adolescent females diagnosed with PD are likely to demonstrate features of PCOS. PCOS
treatment could positively alter the disease course of PD. As such, surgical providers
should consider referring adolescent females with PD to endocrinologists, gynecologists,
and adolescent medicine specialists for evaluation of PCOS.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric and Adolescent GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The American Society of Colon and Rectal Surgeons’ clinical practice guidelines for the management of pilonidal disease.Dis Colon Rectum. 2019; 62: 146-157
- The psychological wellbeing of patients following excision of a pilonidal sinus.J Wound Care. 2012; 21: 595-600
- Polycystic ovary syndrome: definition, aetiology, diagnosis, and treatment.Nat Rev Endocrinol. 2018; 14: 270-284
- Cutaneous findings and systemic associations in women with polycystic ovary syndrome.JAMA Dermatology. 2016; 152: 391-398
- Hirsutism and acne in polycystic ovary syndrome.Best Pract Res Clin Obstet Gynaecol. 2004; 18: 737-754
- ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Fertil Steril. 2004; 81: 19-25
- An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence.Horm Res Paediatr. 2017; 88: 371-395
- Disorders of excessive hair growth in the adolescent.Obstet Gynecol Clin North Am. 2000; 27: 79-99
- Polycystic ovary syndrome and genetic predisposition: a review article.Eur J Obstet Gynecol Reprod Biol. 2019; 3100060
- Pilonidal disease and hidradentitis.Surg Clin N Am. 2009; 89: 689-701
- Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross-sectional study among 2465 patients.Br J Dermatol. 2019; 181: 1198-1206
- Comorbidities of hidradenitis suppurativa, multidisciplinary approach and patient support: a 3-year single center clinical experience.Exp Dermatol. 2017; 26: 15-16
- The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis.Dermatol Ther. 2018; 8: 557-569
- Timeline of recurrence after primary and secondary pilonidal sinus surgery.Dis Colon Rectum. 2007; 50: 1928-1934
- Does technique alter quality of life after pilonidal sinus surgery?.Am J Surg. 2005; 190: 388-392
- Criteria, phenotypes and prevalence of polycystic ovary syndrome.Minerva Ginecologica. 2019; 71: 211-223
- Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome.Endocr Rev. 2015; 36: 487-525
- Adolescent female acne: etiology and management.J Pediatr Adolesc Gynecol. 2008; 21: 171-176
- Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.Hum Reprod. 2018; 33: 1602-1618
- PASH treated successfully with infliximab.Exp Dermatol. 2018; 27: 22-23
- Hidradenitis suppurativa in the paediatric and elderly population: Our hospital experience.Exp Dermatol. 2017; 26: 20-21
- Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa.Br J Dermatol. 2018; 178: 917-924
- Hidradenitis suppurative is associated with polycystic ovary syndrome: a population-based analysis in the United States.J Invest Dermatol. 2018; 138: 1288-1292
- P-326 perinatal outcome of 120 children born from oocyte in vitro maturation treatment.Hum Reprod. 2010; 25
- Laser hair epilation: is there a role in pilonidal sinus disease?.Br J Dermatol. 2018; 179: 123
- Incidental extraspinal findings at lumbar spine magnetic resonance imaging.Spine. 2015; 40: 1436-1443
- LHRH analogues and PCO disease: validity of the use of Enantone depot in the treatment of the disease.Acta Eur Fertil. 1992; 23: 293-295
- Diagnosis and treatment of polycystic ovary syndrome.Am Fam Physician. 2016; 94: 106-113
- Pilonidal sinus disease.J Visc Surg. 2013; 150: 237-247
- Practice parameters for the management of pilonidal disease.Dis Colon Rectum. 2013; 56: 1021-1027
- The role of oral contraceptive pills in hidradenitis suppurativa: a cohort study.Life. 2021; 697: 1-11
- Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality.Br J Dermatol. 2016; 174: 970-978
- Hormonal contraceptives and dermatology.Am J Clin Dermatol. 2021; 22: 69-80
Article info
Publication history
Published online: August 19, 2022
Accepted:
August 11,
2022
Received in revised form:
July 30,
2022
Received:
March 1,
2022
Footnotes
Conflict of Interest Statement: All authors have no disclosures/conflicts of interest to report.
The abstract was presented at the 35th North American Society for Pediatric and Adolescent Gynecology Annual Clinical and Research Meeting, March 21, 2021.
Identification
Copyright
© 2022 Published by Elsevier Inc. on behalf of North American Society for Pediatric and Adolescent Gynecology.
